ArticleAmerican journal of translational research2026
Impact of transfusion-associated iron overload on hepatic and renal function in patients with aplastic anemia: a retrospective cohort study of 145 cases.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTransfusion-associated iron overload is a common complication in patients with transfusion-dependent aplastic anemia (AA). This study aimed to evaluate its impact on hepatic and renal function in AA patients.
methodsA total of 145 transfusion-dependent AA patients were included in this study. Baseline iron overload was evaluated using serum ferritin, and organ function was assessed via hepatic and renal biomarkers. Univariate and multivariable regression analyses were conducted to examine the associations between ferritin levels and organ dysfunction. The potential modifying effect of iron chelation therapy on these associations was also evaluated.
resultsElevated serum ferritin levels were significantly associated with increased alanine aminotransferase and lower estimated glomerular filtration rate, indicating liver and kidney dysfunction. Iron chelation therapy attenuated these associations, suggesting its protective role against iron overload-related organ dysfunction. Ferritin was independently associated with liver and kidney dysfunction, and these associations were modified by chelation exposure.
conclusionsTransfusion-associated iron overload exerts a significant adverse effect on hepatic and renal functions in AA patients. Iron chelation therapy appears to mitigate these effects, supporting its clinical use in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.